A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2022-05-28
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-06-19 (study day 14); relationship: not assessed
moderate
assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-07-14 (study day 39); relationship: N
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-07-19 (study day 44); relationship: N
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-07-24 (study day 49); relationship: not assessed
Data queries
No data queries.